Sertraline Hydrochloride Tablet
Product Images NDC 50090-7692

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sertraline Hydrochloride (NDC 50090-7692). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907692)

The image shows a white drug label for SERTRALINE HYDROCHLORIDE 50 mg tablets, an oral human prescription drug by A-S Medication Solutions. The label includes the NDC number 50090-7692-0, lot number, storage instructions to keep at 20 to 25°C, and a note that each film-coated tablet contains 50 mg sertraline hydrochloride USP equivalent to 50 mg sertraline. The package contains 90 tablets.*

FDA Label Image

Image Description (Struct)

Chemical structure of sertraline hydrochloride, showing the molecular arrangement of the active ingredient including two chlorine atoms attached to a phenyl ring and a methylamino group on a cyclohexane ring.*

FDA Label Image

Table 3 (Table 3)

Table showing common adverse reactions in pooled placebo-controlled trials for sertraline hydrochloride versus placebo. Categories include cardiac, eye, gastrointestinal, general disorders, metabolism, nervous system, psychiatric, reproductive system, and skin disorders, with reaction percentages for sertraline and placebo groups. Data highlight higher incidence of nausea, diarrhea, insomnia, and other effects in sertraline-treated patients.*

FDA Label Image

Table1 (Table1)

A table titled 'Recommended Daily Dosage of sertraline hydrochloride in Patients with MDD, OCD, PD, PTSD, and SAD' displaying starting doses and therapeutic ranges for adults and pediatric patients. It lists specific doses for major depressive disorder (MDD), obsessive-compulsive disorder (OCD), panic disorder (PD), post-traumatic stress disorder (PTSD), and social anxiety disorder (SAD).*

FDA Label Image

Table2 (Table2)

A data table titled 'Table 2: Risk Differences of the Number of Cases of Suicidal Thoughts or Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients.' The table presents age ranges and associated drug-placebo differences in the number of patients with suicidal thoughts or behaviors per 1000 patients treated, showing increases for ages under 18 and 18-24, and decreases for ages 25-64 and 65 and older.*

FDA Label Image

Image Description (Table4)

A table showing the most common sexual adverse reactions (≥2% and twice placebo) in men and women for sertraline hydrochloride versus placebo. It includes data for men only and women only groups with specific reaction percentages such as ejaculation failure, decreased libido, erectile dysfunction, and related conditions from pooled controlled trials in adults with various disorders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.